Union Electric Company
UEPEM News Today: Stay Updated with the Latest Union Electric Company News in Real Time
Find UEPEM news now at Meyka AI. Stay informed with the latest Union Electric Company stocks updates, including price news, market analysis, and expert insights.
Saregama India Surges 15.9% on Earnings Day as Volume Hits 97x Average
SAREGAMA.NS stock jumps 15.9% to INR 385.8 on earnings day with volume surging 97x above average on NSE.
Marvel Discovery Corp. (MARVF) Crashes 96.5% on Exploration Setbacks
MARVF stock plummets 96.5% to $0.0002 as mineral exploration company faces severe financial distress and operational challenges.
Vishal Mega Mart Q4 Profit Soars 46% YoY to ₹168 Crore, Yet Shares Drop 4.4%
Vishal Mega Mart delivered a strong financial performance in the fourth quarter of FY26 as the company reported a sharp rise in net profit and revenue growth. Despite the impressive earnings, the company’s shares declined nearly 4.4% during trading as investors reacted cautiously to valuation concerns and broader stock market sentiment. The company announced that…
Cape Range Limited (CAG.AX) Flat at A$0.09 on Volume Spike
CAG.AX stock trades flat at A$0.09 with volume spike to 8,900 shares. Software company faces headwinds with negative earnings and C-grade rating.
Easy Trip Planners Surges 12.4% as Travel Demand Rebounds
EASEMYTRIP.NS stock jumps 12.4% on strong trading volume. Easy Trip Planners rebounds as travel sector gains momentum on NSE.
MGRM Directors File Initial Ownership Forms, May 14, 2026
Two MGRM directors file Form 3 initial ownership disclosures for stock options. Gray Colleen and Van Kirk Richard Lee Jr report option holdings.
ATUSF: BMO Capital Maintains Market Perform Rating, May 2026
BMO Capital maintains Market Perform rating on ATUSF, raising price target to C$49 from C$44 on May 13, 2026.
Oryzon Genomics Climbs 0.43% as Iadademstat Shows 100% Response Rate
ORY.MC stock rises on positive iadademstat clinical data showing 100% overall response rate in acute myeloid leukemia trials.
Kinarus Therapeutics (PRFN.SW) Drops 8.1% on Clinical-Stage Biotech Headwinds
PRFN.SW stock falls 8.1% to CHF0.0362. Kinarus Therapeutics faces clinical development challenges with KIN001 p38 MAPK inhibitor candidate.